With the global obesity drug market expected to cross $130 billion by 2034, big pharmaceutical companies are racing to grab a slice of what’s fast becoming the hottest space in healthcare. To figure out who’s best placed to win big, FENIX has released its Obesity Power Rankings, naming the Top 10 companies leading the charge.
More than 20 companies were evaluated using 15+ weighted criteria—including pipeline strength, clinical differentiation, and commercial readiness—to arrive at a final score out of five. For those wanting a deeper dive into the scoring framework, FENIX says its team is open to discussions. Below is a company-by-company breakdown, along with the key factors pushing each one up—or holding it back.
Lilly (4.9/5)
Lilly continues to dominate the obesity space and remains the clear market leader. Its tirzepatide franchise became the world’s top-selling drug in 2025, overtaking Merck’s Keytruda and generating over $36 billion in annual revenue.
While Lilly’s late-stage pipeline looks strong enough to protect its leadership, the spotlight now shifts to the orforglipron launch expected in Q2 2026. That said, with Novo’s Wegovy Pill showing slightly better efficacy, Lilly’s commercial team may—unusually—have to play catch-up.
Novo Nordisk (4.8/5)
As the company that kick-started the modern obesity boom with semaglutide, Novo entered 2026 facing a tough mix of execution challenges and slowing innovation. These pressures led to its first negative annual sales outlook since semaglutide took off.
Novo is now betting heavily on the launches of injectable 7.2mg Wegovy, Wegovy Pill, and CagriSema to defend its US market share and win back investor confidence. While these launches may help in the short term, questions remain about whether Novo has a true long-term successor to semaglutide.
Pfizer (4.1/5)
Pfizer has surged up the rankings following its $10 billion Metsera acquisition and a licensing deal with YaoPharma in 2025. After earlier disappointments—such as the discontinuation of danuglipron and lotiglipron—Pfizer finally seems to have built a differentiated obesity pipeline.
This time, the company appears well-positioned to fully use its massive commercial and manufacturing muscle.
Roche (4.0/5)
Roche may be a newcomer to cardiometabolic diseases, but its ambition is clear: it wants to be a Top 3 obesity player. Encouraging Phase 2 topline results for CT-388 have boosted confidence, and attention is now firmly on the Phase 2 petrelintide data expected in H1 2026.
That readout could be a turning point—not just for Roche’s partnership with Zealand, but for its broader obesity strategy.
AstraZeneca (3.6/5)
AstraZeneca could be the dark horse in this race. The company quietly advanced a wide mid-stage pipeline throughout 2025, and multiple Phase 2 results are due in 2026.
Its licensing deal with CSPC Pharmaceuticals, which added a monthly dual agonist, further strengthens AstraZeneca’s case as a serious contender for a top-three spot.
Amgen (3.3/5)
Amgen is making a focused bet on MariTide, banking on its extended dosing schedule as a key differentiator. Quarterly maintenance dosing stands out—but investor confidence took a hit after Phase 2 tolerability concerns surfaced at ADA 2025.
Whether Amgen can overcome those concerns remains a big question.
Boehringer Ingelheim (3.0/5)
Boehringer Ingelheim is set to become the first real challenger to the Lilly–Novo duopoly. Phase 3 data from its survodutide program is expected to start rolling out in H1 2026.
Even with strong results, BI may still need to broaden its pipeline beyond its Phase 2 triple agonist to stay competitive in the long run.
Regeneron (2.9/5)
Regeneron was once seen as taking a side route in obesity, focusing on lean mass–sparing therapies. That perception changed in June 2025, when it in-licensed olatorepatide, signaling much bigger ambitions.
Like BI and Amgen, however, Regeneron may need a more diversified portfolio to truly challenge the leaders.
Zealand Pharma (2.4/5)
Led by CEO Adam Steensburg, Zealand wants to put an end to what he calls the “Weight Loss Olympics.” The company is betting big on amylin as the next foundational obesity drug class.
After partnering with Roche on petrelintide, all eyes are now on the Phase 2 ZUPREME-1 readout, which will offer the first real test of whether petrelintide can live up to its promise.
Kailera Therapeutics (2.2/5)
Kailera has licensed ribupatide, a GLP-1/GIP dual agonist from China’s Hengrui that has already shown strong late-stage weight loss results in Chinese patients. The company has launched its own Phase 3 trials, testing higher doses and longer treatment durations.
The big question now: will Kailera partner with Big Pharma—or try to go it alone with a direct-to-patient US commercial model?
Source_https://www.fiercepharma.com/sponsored/obesity-power-rankings-who-will-challenge-lilly-and-novo